Dynavax Technologies Stock (NASDAQ: DVAX)

Dynavax Technologies

DYNAVAX TECHNOLOGIES CORP

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Gene therapy

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

CAPR

CRSP

DVAX

MRNA

NVAX

SLDB

SRPT

TSHA

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Vinay Prasad&#39;s Appointment To FDA&#39;s CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation

Downgrades

Price Target

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty

bank stocks fall chart shutter

Pre-Market Outlook

Markets

CMCO

FLNC

PLYA

QTTB

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

Press Releases

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

Deep Track Capital Releases Investor Presentation on Dynavax Technologies

Earnings

Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

/C O R R E C T I O N -- Dynavax Technologies/

Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting

CTRX

HPTX

TARS

ZSPH

Ardelyx

Biohaven

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dyne Therapeutics

89bio

Geron

GRAIL

Gyre Therapeutics

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Janux Therapeutics

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Arcus Biosciences

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

JMP Securities

Goldman Sachs

Citizens Capital Markets

HC Wainwright & Co.

Comments

Dynavax Technologies

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell